Another important fact is that currently, targeted cancer treatment for individual patients is carried out by analysis of primary tumors. The difficulties with this approach are that the primary tumors contain very few cells that cause metastasis or reoccurrence, and samples for analysis are obtained by needle core biopsies or surgical removal of tumor tissue-which are invasive procedures and prohibit the extraction of tissue from locations inaccessible by surgery.
So there is the need for non-invasive methods capable of detecting CTCs independent of the epithelial cell marker.
Ad Statistics
Times Displayed: 50393
Times Visited: 1435 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Details and conclusions described in Gut [1]
(1) The OBP-401-based CTC capture system developed by Okayama University can be used to genetic testing of CTCs with mesenchymal characteristics, including GISTs and osteosarcomas.
(2) Combining OBP-401-based CTC capture system and genetic testing enabled the detection of KRAS and BRAF mutations in blood samples taken from patients with colorectal cancer. Notably, these mutations were determined to be identical to the ones seen in the primary tumours of the patients.
(3) This technology requires large scale testing.
References and information
[1] Shigeyasu K, Tazawa H, Hashimoto Y,et al., Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non- invasive companion diagnostics, Gut Published Online First: [28 May 2014] doi:10.1136/gutjnl-2014-306957
Correspondence to
Professor Toshiyoshi Fujiwara,
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
EMAIL: toshi_f@md.okayama-u.ac.jp
[2] The manufacturer of OBP-401 (TelomeScan) is Oncolys BioPharma Inc:
http://www.oncolys.com/en/pipeline/obp-1101.html
[3] Patents owned by Oncolys BioPharma Inc:
http://www.oncolys.com/en/company-information/patent.html
Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku ,
Okayama 700-8530, Japan
Planning and Public Information Division, Okayama University
E-mail: www-adm@adm.okayama-u.ac.jp
Website: http://www.okayama-u.ac.jp/index_e.html
Back to HCB News
